Cargando…
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and reliable incidence rates are lacking. In this study, we characterized, defined the incidence over time and studied prognostic implications in all t-AML patients diagnosed in Sweden between 1997 and 2015. Data were r...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071134/ https://www.ncbi.nlm.nih.gov/pubmed/36005563 http://dx.doi.org/10.3324/haematol.2022.281233 |
_version_ | 1785019140563533824 |
---|---|
author | Nilsson, Christer Linde, Fredrika Hulegårdh, Erik Garelius, Hege Lazarevic, Vladimir Antunovic, Petar Cammenga, Jörg Deneberg, Stefan Eriksson, Anna Jädersten, Martin Björkvall, Cecilia Kämpe Möllgård, Lars Wennström, Lovisa Ölander, Emma Höglund, Martin Juliusson, Gunnar Lehmann, Sören |
author_facet | Nilsson, Christer Linde, Fredrika Hulegårdh, Erik Garelius, Hege Lazarevic, Vladimir Antunovic, Petar Cammenga, Jörg Deneberg, Stefan Eriksson, Anna Jädersten, Martin Björkvall, Cecilia Kämpe Möllgård, Lars Wennström, Lovisa Ölander, Emma Höglund, Martin Juliusson, Gunnar Lehmann, Sören |
author_sort | Nilsson, Christer |
collection | PubMed |
description | Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and reliable incidence rates are lacking. In this study, we characterized, defined the incidence over time and studied prognostic implications in all t-AML patients diagnosed in Sweden between 1997 and 2015. Data were retrieved from nationwide population-based registries. In total, 6,779 AML patients were included in the study, of whom 686 (10%) had t-AML. The median age for t-AML was 71 years and 392 (57%) patients were females. During the study period, the incidence of t-AML almost doubled with a yearly increase in t-AML of 4.5% (95% confidence interval: 2.8%-6.2%), which contributed significantly to the general increase in AML incidence over the study period. t-AML solidly constituted over 10% of all AML cases during the later period of the study. Primary diagnoses with the largest increase in incidence and decrease in mortality rate during the study period (i.e., breast and prostate cancer) contributed significantly to the increased incidence of t-AML. In multivariable analysis, t-AML was associated with poorer outcome in cytogenetically intermediate- and adverse-risk cases but t-AML had no significant impact on outcome in favorable-risk AML, including core binding leukemias, acute promyelocytic leukemia and AML with mutated NPM1 without FLT3-ITD. We conclude that there is a strong increase in incidence in t-AML over time and that t-AML constitutes a successively larger proportion of the AML cases. Furthermore, we conclude that t-AML confers a poor prognosis in cytogenetically intermediate- and adverse-risk, but not in favorable-risk AML. |
format | Online Article Text |
id | pubmed-10071134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-100711342023-04-05 Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications Nilsson, Christer Linde, Fredrika Hulegårdh, Erik Garelius, Hege Lazarevic, Vladimir Antunovic, Petar Cammenga, Jörg Deneberg, Stefan Eriksson, Anna Jädersten, Martin Björkvall, Cecilia Kämpe Möllgård, Lars Wennström, Lovisa Ölander, Emma Höglund, Martin Juliusson, Gunnar Lehmann, Sören Haematologica Article - Acute Myeloid Leukemia Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and reliable incidence rates are lacking. In this study, we characterized, defined the incidence over time and studied prognostic implications in all t-AML patients diagnosed in Sweden between 1997 and 2015. Data were retrieved from nationwide population-based registries. In total, 6,779 AML patients were included in the study, of whom 686 (10%) had t-AML. The median age for t-AML was 71 years and 392 (57%) patients were females. During the study period, the incidence of t-AML almost doubled with a yearly increase in t-AML of 4.5% (95% confidence interval: 2.8%-6.2%), which contributed significantly to the general increase in AML incidence over the study period. t-AML solidly constituted over 10% of all AML cases during the later period of the study. Primary diagnoses with the largest increase in incidence and decrease in mortality rate during the study period (i.e., breast and prostate cancer) contributed significantly to the increased incidence of t-AML. In multivariable analysis, t-AML was associated with poorer outcome in cytogenetically intermediate- and adverse-risk cases but t-AML had no significant impact on outcome in favorable-risk AML, including core binding leukemias, acute promyelocytic leukemia and AML with mutated NPM1 without FLT3-ITD. We conclude that there is a strong increase in incidence in t-AML over time and that t-AML constitutes a successively larger proportion of the AML cases. Furthermore, we conclude that t-AML confers a poor prognosis in cytogenetically intermediate- and adverse-risk, but not in favorable-risk AML. Fondazione Ferrata Storti 2022-08-25 /pmc/articles/PMC10071134/ /pubmed/36005563 http://dx.doi.org/10.3324/haematol.2022.281233 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article - Acute Myeloid Leukemia Nilsson, Christer Linde, Fredrika Hulegårdh, Erik Garelius, Hege Lazarevic, Vladimir Antunovic, Petar Cammenga, Jörg Deneberg, Stefan Eriksson, Anna Jädersten, Martin Björkvall, Cecilia Kämpe Möllgård, Lars Wennström, Lovisa Ölander, Emma Höglund, Martin Juliusson, Gunnar Lehmann, Sören Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications |
title | Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications |
title_full | Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications |
title_fullStr | Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications |
title_full_unstemmed | Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications |
title_short | Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications |
title_sort | characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications |
topic | Article - Acute Myeloid Leukemia |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071134/ https://www.ncbi.nlm.nih.gov/pubmed/36005563 http://dx.doi.org/10.3324/haematol.2022.281233 |
work_keys_str_mv | AT nilssonchrister characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT lindefredrika characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT hulegardherik characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT gareliushege characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT lazarevicvladimir characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT antunovicpetar characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT cammengajorg characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT denebergstefan characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT erikssonanna characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT jaderstenmartin characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT bjorkvallceciliakampe characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT mollgardlars characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT wennstromlovisa characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT olanderemma characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT hoglundmartin characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT juliussongunnar characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications AT lehmannsoren characterizationoftherapyrelatedacutemyeloidleukemiaincreasingincidenceandprognosticimplications |